...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current medical research and opinion >Effect of preventive treatment with botulinum toxin type A on acute headache medication usage in migraine patients.
【24h】

Effect of preventive treatment with botulinum toxin type A on acute headache medication usage in migraine patients.

机译：A型肉毒杆菌毒素预防性治疗对偏头痛患者急性头痛药物的使用效果。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To evaluate the impact of preventive treatment of migraine with botulinum toxin type A (BoNT-A as BOTOX) on the amount of acute headache medications used. RESEARCH DESIGN AND METHODS: Data from four studies of BoNT-A treatment for migraine were pooled for an aggregate analysis. All studies were at least 12 weeks in duration. For each study, the amounts of headache medications used at weeks 8-12 following BoNT-A treatment were compared with pretreatment baseline amounts and expressed preventive headache care considering acute as a percentage change. MAIN OUTCOME MEASURES: The mean value for the reduction in medication usage was calculated by pooling data from the individual studies and weighting the data according to the sample size of each study. RESULTS: Four studies (one published, and three presented as recent meeting abstracts) with a total of 167 patients quantified acute headache medication use before and after BoNT-A treatment. The weighted average reduction in medication usage (primarily triptans) was 57% (range 38-75%). CONCLUSIONS: The results of this pooled analysis indicated a 57% reduction in acute headache medication use in the 8- to 12-week period following injection of BoNT-A. A reduction of this magnitude could represent substantial savings in the costs of acute medications. This could help to offset the total cost of treatment and suggests BoNT-A may be a cost-reasonable option for medication offsets alone especially in patients with chronic headache with higher acute medication use. Additional larger controlled efficacy and safety studies must be done to confirm these results since three of the four studies were preliminary research and of different study types. Further prospective studies of direct and indirect costs, including those for disability and lost productivity, are needed to evaluate the overall impact of BoNT-A therapy on the economic, societal, and individual burden of migraine headache.
机译：目的：评估预防性治疗A型肉毒杆菌毒素（BoNT-A为BOTOX）对偏头痛对急性头痛药物使用量的影响。研究设计和方法：汇总了BoNT-A治疗偏头痛的四项研究的数据，进行了汇总分析。所有研究持续至少12周。对于每项研究，将BoNT-A治疗后第8-12周使用的头痛药物的量与治疗前的基线量进行比较，并考虑到急性百分比变化表示预防性头痛治疗。主要观察指标：减少药物用量的平均值是通过汇总各个研究的数据并根据每个研究的样本量对数据加权来计算的。结果：总共有167位患者的四项研究（一项已发表，三项是最近的会议摘要）对BoNT-A治疗前后的急性头痛药物使用进行了量化。药物使用的加权平均减少量（主要是曲普坦）为57％（范围38-75％）。结论：该汇总分析的结果表明，在注射BoNT-A后的8至12周内，急性头痛药物的使用减少了57％。这种幅度的降低可能代表着急性药物成本的大量节省。这可以帮助抵消总的治疗费用，并建议BoNT-A可能是单独使用药物抵消的一种成本合理的选择，尤其是在患有慢性头痛且急性药物用量较高的患者中。由于四项研究中的三项是初步研究且属于不同研究类型，因此必须进行其他更大的受控疗效和安全性研究以确认这些结果。为了评估BoNT-A治疗对偏头痛的经济，社会和个人负担的总体影响，还需要对直接和间接费用（包括残疾和生产力损失的费用）进行进一步的前瞻性研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号